--- title: "Pre-market trend | WuXi Biologics (2269.HK) 5/11 Pharmaceutical technology sets the direction, initial results in new drug development?" type: "News" locale: "en" url: "https://longbridge.com/en/news/285907712.md" description: "Yesterday, WuXi Biologics' stock price quickly rose to HKD 120, with a trading volume reaching HKD 800 million, indicating active market participation. The MACD daily chart generated a golden cross above the zero line, further confirming the bullish trend in the pharmaceutical technology sector, with strong short-term performance. The current stock price is firmly above key technical levels, suggesting a positive outlook for the future. Amid the wave of pharmaceutical technology development, WuXi Biologics, as an important part of the biopharmaceutical CDMO platform, is actively engaged in new drug varieties and industry chain integration, receiving broad market optimism. Additionally, positive developments in Sino-U.S. trade relations and advancements in COVID-19 drug research provide a more solid foundation for expanding its market share. In terms of technical indicators, after the MACD daily chart showed a golden cross signal, it formed upward support on the moving averages, with significant buying volume and price coordination, and the continued warming of market confidence brings necessary conditions for profitability. However, it is important to note that the market's high valuation carries certain bubble risks, and investors should grasp market rhythms and adjust dynamically in a timely manner. Risk warnings include international legal regulations, global industrial chain arrangements, and vaccine development progress, which will continue to pose threats to its profitability. Market changes are rapid, and investors must base their decisions on well-equipped information to make rational choices. This article only provides technical analysis and market information for reference and does not constitute any investment advice. The market carries uncertainties, and investors should make independent decisions based on their own circumstances" datetime: "2026-05-12T01:00:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285907712.md) - [en](https://longbridge.com/en/news/285907712.md) - [zh-HK](https://longbridge.com/zh-HK/news/285907712.md) --- # Pre-market trend | WuXi Biologics (2269.HK) 5/11 Pharmaceutical technology sets the direction, initial results in new drug development? Yesterday, WuXi Biologics' stock price quickly rose to HKD 120 at the close, with a trading volume reaching HKD 800 million, indicating active market participation. The MACD daily line generated a golden cross above the zero axis, further confirming the bullish trend in the pharmaceutical technology sector, with strong short-term performance. The current stock price is firmly above key technical positions, suggesting a positive outlook for the future. In the wave of pharmaceutical technology development, WuXi Biologics, as an important part of the biopharmaceutical CDMO platform, has shown active performance in new drug varieties and industrial chain integration, gaining widespread market optimism. Additionally, positive developments in China-U.S. trade relations and advancements in COVID-19 drug research provide a more solid foundation for its market share expansion. In terms of technical indicators, after the MACD daily line showed a golden cross signal, it formed upper support on the moving averages, with significant buying volume and price coordination, and the continued warming of market confidence brings necessary conditions for corporate profitability. However, it is important to note that the market's high valuation carries certain bubble risks, and investors should grasp market rhythms and adjust dynamically in a timely manner. Risk warning: Factors such as international legal regulations, global industrial chain arrangements, and vaccine development progress will continue to pose risks to its profitability. The market changes rapidly, and investors must base their decisions on well-equipped information to make rational choices. _This article only provides technical analysis and market information for reference and does not constitute any investment advice. The market carries uncertainties, and investors should make independent decisions based on their own circumstances._ ### Related Stocks - [02269.HK](https://longbridge.com/en/quote/02269.HK.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [159615.CN](https://longbridge.com/en/quote/159615.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [513060.CN](https://longbridge.com/en/quote/513060.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [WXXWY.US](https://longbridge.com/en/quote/WXXWY.US.md) ## Related News & Research - [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md) - [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md) - [HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations](https://longbridge.com/en/news/286197909.md) - [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md) - [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)